Frequently Asked Questions
What is a PSL?
Azaya has discovered and developed a proprietary Protein Stabilized Liposomes (PSLTM) technology platform for enhanced delivery of water insoluble drugs including safer and more efficacious chemotherapeutics.
The PSL Technology:
- Allows further development of experimental drugs that up to now have been difficult to deliver to the marketplace due to toxicity or formulation issues
- Allows reformulation of approved, marketed drugs with proven efficacy
- This process will reduce the risk, duration and cost of development
- Prolongs the life cycle of currently available chemotherapeutics or drugs in development
- Will explore the future for delivering cancer drugs in combination in a single,
targeted drug delivery system - Extensive product pipeline and potential to expand to non-oncology therapeutics
- Initial preclinical xenograph studies have shown improved safety and efficacy
verses the parent compounds - Robust cost-effective manufacturing process producing nano-particlesized liposomes
- This process solves major problems of earlier generation liposomes with many potential therapeutic benefits over currently available technologies
- Utilizes 100% FDA-approved ingredients
- Allows entry into existing multi-billion dollar markets
- Excellent IP position
- Strong competitive advantages verses other drug delivery technologies
- Highly experienced management team
